Printed From BioPortfolio.com
MiniVax, Inc. Company Profile
14:27 EST 16th February 2019 | BioPortfolio
MiniVax is a New Orleans, LA based company that specializes in the
research and development of novel vaccines and therapeutics for the
treatment and prevention of opportunistic fungal and bacterial
infections. MiniVaxâs lead product is a vaccine against the
opportunistic fungal infection Pneumocystis pneumonia (PCP), which
predominately affects immunocompromised individuals. MiniVax
anticipates beginning in-human FDA clinical trials for the vaccine in
2013. A secondary focus of MiniVax is the development of a
monoclonal antibody therapeutic for the treatment of those individuals
who are already suffering from PCP. MiniVax occupies office
and laboratory space at the New Orleans BioInnovation Center (NOBIC).
News Articles
None
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
MiniVax is a New Orleans, LA based company that specializes in the research and development of novel vaccines and therapeutics for the treatment and prevention of opportunistic fu...
More Information about "MiniVax, Inc." on BioPortfolio
We have published hundreds of MiniVax, Inc. news stories on BioPortfolio along with dozens of MiniVax, Inc. Clinical Trials and PubMed Articles about MiniVax, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MiniVax, Inc. Companies in our database. You can also find out about relevant MiniVax, Inc. Drugs and Medications on this site too.
